BotswanaTuberculosis profile
Population  2014 2.2 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.62 (0.44–0.82) 28 (20–37)
Mortality (HIV+TB only) 1 (0.8–1.3) 47 (36–59)
Prevalence  (includes HIV+TB) 7.9 (4.4–12) 354 (199–554)
Incidence  (includes HIV+TB) 8.5 (8–9.1) 385 (361–410)
Incidence (HIV+TB only) 4.5 (4.1–5) 204 (183–227)
         
Case detection, all forms (%) 70 (66–75)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.5–3.5) 6.6 (2.4–11)
MDR-TB cases among notified pulmonary
TB cases
100 (61–140) 56 (20–90)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 218   439
Pulmonary, clinically diagnosed 1 819   403
Extrapulmonary 1 008   132
       
Total new and relapse 6 019    
Previously treated, excluding relapses      
Total cases notified 6 019    
Among 6 017 new and relapse cases:
419 (7%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 10 (<1%) 62 (6%) 73
Laboratory-confirmed RR-/MDR-TB cases     41
Patients started on MDR-TB treatment ***     73
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 496 (91)
HIV-positive TB patients 3 280 (60)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 132 (95)
HIV-positive TB patients on antiretroviral therapy (ART) 2 546 (78)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (73) 7 254
Previously treated cases, excluding relapse, registered in 2013 (60) 124
HIV-positive TB cases, all types, registered in 2013 (71) 4 083
RR-/MDR-TB cases started on second-line treatment in 2012 (70) 63
XDR-TB cases started on second-line treatment in 2012 (100) 1
Laboratories 2014  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 2.3
Drug susceptibility testing (per 5 million population) 2.3
Sites performing Xpert MTB/RIF 36
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-30 Data: www.who.int/tb/data